The biotech industry offers numerous opportunities for investors who are willing to wait for the underlying business to reach its full potential.
One such rising star is Recursion Pharmaceuticals (RXRX), which uses artificial intelligence (AI), robotic biology, and massive phenotypic screening to automate and scale drug discovery. Instead of relying on traditional hypothesis-driven R&D, Recursion created a discovery platform, which is a scalable, AI-driven discovery engine with pipeline-agnostic capabilities.
